Paper Details

  1. Home
  2. Paper Details

Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study.

Author: BahlisNizar, GriesKatharine S, HeuckChristoph, IidaShinsuke, IshikawaTakayuki, ItoShigeki, KimKihyun, MateosMaria-Victoria, MinChang Ki, NahiHareth, ParasrampuriaDolly A, QiMing, QinXiang, UsmaniSaad Z, YehSu Peng

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Equivalence TrialA clinical trial designed to show that a new treatment is equivalent in efficacy/safety to an existing treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This subgroup analysis of Asian patients from the COLUMBA study showed that subcutaneous daratumumab (DARA SC) was comparable to intravenous daratumumab (DARA IV) in terms of efficacy, pharmacokinetic profile, safety, and patient-reported satisfaction.
Paper Details　
Original Abstract of the Article :
The phase 3 COLUMBA study demonstrated noninferiority of subcutaneous daratumumab (DARA SC) to intravenous daratumumab (DARA IV) in relapsed or refractory multiple myeloma. We present a subgroup analysis of Asian patients from COLUMBA. Eligible patients had ≥ 3 prior lines of therapy, in...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7960612/

データ提供：米国国立医学図書館（NLM）

Subcutaneous Daratumumab: A New Oasis in the Desert of Multiple Myeloma

Multiple myeloma (MM), a type of blood cancer affecting plasma cells, can be a challenging condition to treat, particularly in cases of relapse or refractoriness. This study explores the efficacy and safety of subcutaneous daratumumab, a monoclonal antibody targeting CD38, in patients with heavily pretreated MM. The researchers conducted a subgroup analysis of Asian patients from a larger clinical trial, finding that subcutaneous daratumumab was comparable to intravenous daratumumab in terms of efficacy, pharmacokinetics, safety, and patient satisfaction.

A New Approach to MM Treatment: Subcutaneous Daratumumab

This study provides valuable information for clinicians managing patients with MM, particularly those who have received multiple prior therapies. The findings suggest that subcutaneous daratumumab offers a comparable treatment option to intravenous daratumumab, with potentially greater convenience and satisfaction for patients. This research underscores the importance of exploring new and innovative approaches to MM treatment.

Navigating the Desert of MM with Subcutaneous Daratumumab

This study offers a promising new approach to managing MM, a condition that often presents significant challenges. The findings suggest that subcutaneous daratumumab offers a viable and potentially more convenient option for patients with MM. This research underscores the importance of continuous exploration in the search for new and effective therapies for this complex and often challenging condition.

Dr.Camel's Conclusion

This study provides a promising oasis in the vast desert of MM treatment. The findings suggest that subcutaneous daratumumab offers a comparable and potentially more convenient option to intravenous daratumumab. This research underscores the importance of exploring new and innovative treatment approaches for MM, seeking to improve the lives of those affected by this challenging condition. This discovery is a testament to the ongoing quest for more effective and patient-centered therapies.

Date :
  1. Date Completed 2021-03-25
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

33599794

DOI: Digital Object Identifier

PMC7960612

Related Literature

Article Analysis
・Effects of daratumumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.